UPC supply chain intelligence for Universe Pharmaceuticals INC: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Universe Pharmaceuticals INC (UPC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ONE-SUPPLIER | ONE-SUPPLIER | 90% | For the fiscal year ended September 30, 2023, one supplier accounted for 29.6% of our total purchases. |
| TWO-SUPPLIERS | TWO-SUPPLIERS | 90% | For the fiscal year ended September 30, 2024, two suppliers accounted for 28.0% and 13.4% of our total purchases, respectively. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CLINICS | CLINICS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| DRUGSTORE-CHAINS | DRUGSTORE-CHAINS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| HOSPITALS | HOSPITALS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| PHARMACEUTICAL-DISTRIBUTORS | PHARMACEUTICAL-DISTRIBUTORS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| BEIJING-CO-LTD | BEIJING-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| CHINA-BEIJING-TONG-REN-TANG-GROUP-CO-LTD | CHINA-BEIJING-TONG-REN-TANG-GROUP-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| CO-LTD | CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| FUZI-LIZHONG-PILL-CHINA-BEIJING-TONG-REN-TANG-GR | FUZI-LIZHONG-PILL-CHINA-BEIJING-TONG-REN-TANG-GR | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| GUANGZHOU-BAIYUNSHAN-PHARMACEUTICAL-HOLDINGS-CO- | GUANGZHOU-BAIYUNSHAN-PHARMACEUTICAL-HOLDINGS-CO- | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| GUANGZHOU-PHARMACEUTICAL-CO-LTD | GUANGZHOU-PHARMACEUTICAL-CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| JIANGXI-ZHONGYUAN-PHARMACEUTICAL-CO-LTD | JIANGXI-ZHONGYUAN-PHARMACEUTICAL-CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| PHARMACEUTICALS-CO-LTD | PHARMACEUTICALS-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| QUANLU-PILL-RENHE-PHARMACEUTICALS-CO | QUANLU-PILL-RENHE-PHARMACEUTICALS-CO | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| SHENRONG-WEISHENG-PILL-CHINA-BEIJING-TONG-REN-TA | SHENRONG-WEISHENG-PILL-CHINA-BEIJING-TONG-REN-TA | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| SHENYANG-DONGXIN-PHARMACEUTICAL-INDUSTRY-CO-LTD | SHENYANG-DONGXIN-PHARMACEUTICAL-INDUSTRY-CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| SHINVA-MEDICAL-INSTRUMENT-CO-LTD | SHINVA-MEDICAL-INSTRUMENT-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| SUPPLY-CO-LTD | SUPPLY-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| YUNNAN-BAIYAO-GROUP-CHINA-RESOURCES | YUNNAN-BAIYAO-GROUP-CHINA-RESOURCES | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| ZHONGYUAN-PHARMACEUTICALS-CO-LTD | ZHONGYUAN-PHARMACEUTICALS-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| UPC-DEBT | Debt stack $2.1B | 90% | Market cache reports total debt of $2.1B. |
| UPC-DEBT-13230 | Warrants outstanding: 0.001 | 90% | xbrl warrant detail from xbrl 2023-03-31. |